
WilmerHale Reps Achillion Pharmaceuticals in Pricing of Secondary Offering of Common Stock

NOVEMBER 17, 2017

Achillion Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson & Johnson Innovation-JJDC, Inc., which shares constitute all of JJDC's equity position in Achillion, at a public offering price of \$2.75 per share. The offering is expected to close on November 20, 2017.

The WilmerHale deal team representing Achillion includes Steven Singer, Cynthia Mazareas, Scott Lunin and Killian Nolan.

[Read Achillion's press release for more details.](#)